Forte Biosciences, Inc. (FBRX)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Forte Biosciences, Inc. (“Forte” or the “Company”) (NASDAQ: FBRX). The investigation concerns whether Forte and certain of its officers and/or directors have violated federal securities laws.


On September 2, 2021, post-market, Forte issued a press release “announc[ing] that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI).”  On this news, Forte’s stock price fell sharply during intraday trading on September 3, 2021.


If you are aware of any facts relating to this investigation, or purchased Forte shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.